Endocrine Abstracts

Background and Aims: The Omnipod^® 5 Automated Insulin Delivery (AID) System, which allows for personalised therapy through customisable glucose targets from 6.1-8.3 mmol/l in 0.55 mmol/l increments recently became commercially available for people with type 1 diabetes (T1D) aged 2 years and older in the United Kingdom (UK). This study aimed to evaluate the early real-world performance of the system in the first cohort of paediatric and young adult UK users.

Methods: A retrospective analysis of continuous glucose monitoring (CGM) and insulin data from Omnipod 5 users with T1D aged 2 to <26 years using ≥5 units of insulin per day in the UK who provided consent (guardian provided consent for those aged <18 years) and had ≥90 days of data with sufficient CGM data (≥75% of days with ≥220 readings) available in the cloud-based data management system was conducted.

Results: Data from 6,631 users in the UK were available at the time of analysis with a median 200 days of use and >1.3 million person-days of data. Preliminary results demonstrated a median time in target range (TIR; 3.9-10.0 mmol/l) of 65.5% (n = 3,471), 64.0% (n = 2,027), and 58.8% (n = 1,133) with use of the 6.1 mmol/l, 6.7 mmol/l, and 7.2-8.3 mmol/l targets, respectively. Time below range (TBR; <3.9 mmol/l) was low (median ≤1.60%) across glucose targets. Use of the lowest target (used by 52.3% of all users) was associated with the highest TIR with some age-related variability (2-5y: 66.2% [n = 83]; 6-12y: 67.9% [n = 1,176]; 13-17y: 64.3% [n = 1,596]; 18-25y: 62.7% [n = 616]) and minimal TBR, with 29.6% of these users achieving clinical targets for both >70% TIR and <4% TBR.

Conclusions: Collectively, these early real-world results of Omnipod 5 use in >6,600 children, adolescents, and young adults with T1D in the UK demonstrate that the highly favourable glycaemic outcomes first reported in the United States are achievable across populations. Additionally, these findings highlight the importance of frequent review of user data by clinical care teams to facilitate optimisation of system settings and support the idea that healthcare providers should consider encouraging users seeking to improve their TIR to decrease their glucose target towards the lowest setting whenever possible.